
When the pandemic began, the UAB Minority Health & Health Disparities Research Center (MHRC) quickly pivoted its focus to COVID-19. Because minority race/ethnicity, obesity, and chronic health conditions are risk factors for severe COVID-19 illness, the MHRC was uniquely qualified to address health disparities in the context of the pandemic.
After the COVID-19 pandemic reached Alabama, medical education leaders at the School of Medicine quickly regrouped to enable students to continue their training.
By now, most of us have heard of the antiviral medication remdesivir, the first drug that was FDA-approved to treat patients with COVID-19. What many don’t know is that the research that led to remdesivir being identified as a treatment for COVID-19 has an important connection to UAB.
This past summer, UAB joined an NIH consortium aimed at better understanding how to employ genomic risk assessments, especially in minority populations, in managing disease.
Summer 2020 was a season of intense emotion and activism, as the killings of George Floyd, Breonna Taylor, Ahmaud Arbery, and others brought millions of people across America into the streets to raise their voices for racial justice.